| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenue | 133,010 | 127,785 | 111,585 | 90,377 |
| Cost of sales | 25,537 | 23,421 | 23,018 | 20,806 |
| Research and development | 42,960 | 46,067 | 46,044 | 31,710 |
| Selling, general and administrative | 61,910 | 63,286 | 57,706 | 50,545 |
| Total operating expenses | 130,407 | 132,774 | 126,768 | 103,061 |
| Income (loss) from operations | 2,603 | -4,989 | -15,183 | -12,684 |
| Interest income | 3,251 | 3,033 | 3,023 | 3,469 |
| Interest expense | 3,606 | 3,589 | 3,596 | 3,586 |
| Other income (expense), net | 395 | 86 | 2,108 | -1,087 |
| Net income (loss) before provision for income taxes | 2,643 | -5,459 | -13,648 | -13,888 |
| (benefit from) provision for income taxes | -262 | 402 | 1,029 | 347 |
| Net income (loss) | 2,905 | -5,861 | -14,677 | -14,235 |
| Net income (loss) per share, basic (in dollars per share) | 0.06 | -0.12 | -0.3 | -0.3 |
| Net income (loss) per share, diluted (in dollars per share) | 0.05 | -0.12 | -0.3 | -0.3 |
| Weighted-average shares of common stock outstanding, basic (in shares) | 50,639,231 | 49,726,823 | 48,889,058 | 47,782,619 |
| Weighted-average shares of common stock outstanding, diluted (in shares) | 56,993,841 | 49,726,823 | 48,889,058 | 47,782,619 |
Mirum Pharmaceuticals, Inc. (MIRM)
Mirum Pharmaceuticals, Inc. (MIRM)